Last reviewed · How we verify
Metronidazole 400 (14 days)
Metronidazole 400 (14 days) is a Nitroimidazole antibiotic Small molecule drug developed by University of Guarulhos. It is currently FDA-approved for Anaerobic bacterial infections, Trichomoniasis, Giardiasis.
Metronidazole is a nitroimidazole antibiotic that disrupts bacterial and parasitic DNA by generating reactive oxygen species after reduction of its nitro group.
Metronidazole is a nitroimidazole antibiotic that disrupts bacterial and parasitic DNA by generating reactive oxygen species after reduction of its nitro group. Used for Anaerobic bacterial infections, Trichomoniasis, Giardiasis.
At a glance
| Generic name | Metronidazole 400 (14 days) |
|---|---|
| Sponsor | University of Guarulhos |
| Drug class | Nitroimidazole antibiotic |
| Target | Bacterial/parasitic DNA |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The drug is activated by anaerobic organisms and parasites through enzymatic reduction of its 5-nitro group, producing reactive intermediates that damage DNA and prevent nucleic acid synthesis. This mechanism makes it effective against anaerobic bacteria and certain protozoan parasites. It is bactericidal and antiprotozoal in action.
Approved indications
- Anaerobic bacterial infections
- Trichomoniasis
- Giardiasis
- Amebiasis
- Bacterial vaginosis
- Clostridioides difficile infection
- Peptic ulcer disease (as part of H. pylori eradication)
Common side effects
- Metallic taste
- Nausea
- Headache
- Diarrhea
- Abdominal discomfort
- Peripheral neuropathy (with prolonged use)
- Seizures (rare)
Key clinical trials
- Comparative Effectiveness of Triple Versus Quadruple Therapy in the Treatment of Helicobacter Pylori Induced Gastritis (PHASE4)
- Effects of Bright Light on Co-occurring Cancer-related Symptoms in Breast Cancer Survivors (NA)
- Comparison of Keverprazan Hydrochloride-Amoxicillin Dual Therapy and Susceptibility-Guided Quadruple Therapy for Helicobacter Pylori Rescue Treatment (PHASE3)
- Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer (PHASE2)
- Surgical Access Combined With Systematically Administered Antibiotics in the Treatment of Peri-implantitis (NA)
- Safety and Efficacy of Two Oral Tinidazole Regimens for Refractory Trichomonas Vaginitis (NA)
- Feasibility Study of the Proposed Test-and-treat Screening Program in Younger Participants With H. Pylori Infection
- Amoxicillin and Metronidazole During or After the Periodontal Treatment (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metronidazole 400 (14 days) CI brief — competitive landscape report
- Metronidazole 400 (14 days) updates RSS · CI watch RSS
- University of Guarulhos portfolio CI
Frequently asked questions about Metronidazole 400 (14 days)
What is Metronidazole 400 (14 days)?
How does Metronidazole 400 (14 days) work?
What is Metronidazole 400 (14 days) used for?
Who makes Metronidazole 400 (14 days)?
What drug class is Metronidazole 400 (14 days) in?
What development phase is Metronidazole 400 (14 days) in?
What are the side effects of Metronidazole 400 (14 days)?
What does Metronidazole 400 (14 days) target?
Related
- Drug class: All Nitroimidazole antibiotic drugs
- Target: All drugs targeting Bacterial/parasitic DNA
- Manufacturer: University of Guarulhos — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Anaerobic bacterial infections
- Indication: Drugs for Trichomoniasis
- Indication: Drugs for Giardiasis
- Compare: Metronidazole 400 (14 days) vs similar drugs
- Pricing: Metronidazole 400 (14 days) cost, discount & access